Markets
Another 2026 outlook Steve Sosnick Chief Strategist Interactive Brokers
(CSA Archive/Getty Images)

Interactive Brokers’ chief strategist sees reasons for caution in ’26

With the looming shift in Fed leadership and growing concern about the AI trade, Interactive Brokers’ chief strategist is penciling in modest losses for stocks next year.

When it comes to markets, stock and options watcher Steve Sosnick is, by nature, a bit cautious.

It’s a characteristic that stems from his years working as a risk manager on options market-making desks, a job that essentially forced him to spend an undue amount of time worrying about what could go wrong with the algorithmic models at the heart of the company’s operations. The experience has left him with something of a bias.

“That bias is toward looking for the monsters under the bed,” said Sosnick, chief strategist for Interactive Brokers, in an interview Monday, after he published his 2026 market outlook, which compared to the mostly bullish forecasts from around Wall Street seems pretty meh.

While stressing that he doesn’t consider himself especially bearish, Sosnick sees the S&P 500 ending 2026 at 6,500, implying a 5% pullback from where the blue chips ended Monday.

That’s the lowest official prediction we’ve seen from Wall Street’s scribes so far during the end-of-year outlook season.

(Previously, the most lackluster forecast we’d seen was Bank of America’s call for stocks to end next year at 7,100, which would be a modest gain of about 4%.)

“As a natural contrarian, if everybody is zigging, perhaps there’s a reason to think about zagging,” he said. “I think there’s room for a bit of retrenchment based on the various factors.”

One major one: depending on President Trump’s choice to lead the US central bank after current Chairman Jerome Powell’s term expires in May, there’s a risk that long-term interest rates could rise, he said.

Powell’s heir apparent is reportedly White House economist Kevin Hassett, whose closeness to the administration and public support for the low-rate policies the president has pushed the previously independent Federal Reserve for has prompted some to worry that longer-term rates could rise if the Fed is seen as insufficiently concerned about inflation.

“Markets have an interesting way of testing new Fed chairs,” Sosnick said. He sees US 10-year yields rising to 4.45% by the end of next year (they’re currently at 4.16%), and suggests that a sharp rise in rates could cause some volatility for stocks.

“In theory, high rates should pressure stock prices,” he said. “In reality it’s not always so cut and dry.”

That’s because the path of the stock market will also depend on other factors, like the state of the US economy and its key growth driver: the AI investment boom.

But there, too, Sosnick sees reason for caution, suggesting investors have become increasingly worried that the investment boom from AI hyperscalers might not pay off for shareholders any time soon.

“It’s only normal, and actually desirable, for investors to get concerned with return on investment,” he said. “This whole AI trade only makes sense if at some point there are bottom-line results.”

And while AI technology clearly has potential for huge economic benefits, its still up in the air which companies will ultimately dominate the space.

“If it was 1998 or 1999, we would all be using Netscape browsers and searching on Yahoo, while connecting via AOL,” Sosnick said, adding, “What it means to me is we dont know who the winners are going to be.”

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.